BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36205627)

  • 1. An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes.
    Kurdi A; Mueller T; Weir N
    Eur J Clin Invest; 2023 Feb; 53(2):e13888. PubMed ID: 36205627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
    Graham DJ; Izurieta HS; Muthuri SG; Zhang D; Sandhu AT; Lu Y; Zhao Y; Feng Y; Eworuke E; Lyu H; Gandotra C; Smith ER; Avagyan A; Wernecke M; Kelman JA; Forshee RA; MaCurdy TE
    J Gen Intern Med; 2021 Dec; 36(12):3802-3809. PubMed ID: 34599472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
    Kashour T; Bin Abdulhak AA; Tlayjeh H; Hassett LC; Noman A; Mohsen A; Al-Mallah MH; Tleyjeh IM
    Am J Ther; 2023 Jul-Aug 01; 30(4):e336-e346. PubMed ID: 33201001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
    Zhang G; Wu Y; Xu R; Du X
    J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
    Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
    BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
    Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
    Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
    Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
    Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
    Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH; Hall AS
    Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.
    Biswas M; Kali MSK
    Sci Rep; 2021 Mar; 11(1):5012. PubMed ID: 33658619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.